查看文章

This review article examines the transformative impact of bevacizumab (Avastin®) in cancer therapy over the past years, focusing on its future potential in oncological applications. Bevacizumab (BCZ), a humanized antibody targeting vascular endothelial growth factor (VEGF), has become a cornerstone in cancer treatment due to its angiogenesis inhibiting properties. The article highlights clinical advancements, such as the development of innovative formulations like cationic liposome conjugation and PEGylated nanoparticles, which enhance targeted delivery and reduce systemic toxicity, improving patient outcomes. The review also delves into the pharmacological challenges of BCZ, including its stability and handling of acidic and basic charge variants. Emerging research on anti-VEGF prolonged release systems and sophisticated drug delivery mechanisms, such as stimuli-responsive hydrogels and …